-
"We have shown for the first time that immediate treatment after a first clinical demyelinating event suggestive of MS can reduce the early neurological damage, which may ultimately delay the development of the debilitating sequelae that characterize adv
-
Rituxan cancer drug proved highly effective against multiple sclerosis in a small mid-stage trial, signaling a potentially more effective way of treating the progressive neurological disease.
-
Merck Serono announced today that patient enrollment has been completed in the CLARITY (CLAdRIbine Tablets Treating MS OrallY) study, a Phase III pivotal clinical trial evaluating the efficacy and safety
-
Serono announced today the initiation of a Phase III clinical trial to evaluate the effect of two dosage regimens of the new formulation of Rebif(R) (interferon beta-1a 44 mcg, three times a week or once a week) on the time to
-
To identify clinical and demographic factors associated with long-term disability in patients with relapsing-remitting multiple sclerosis.
-
The Roskamp Institute announced today its participation in a pharmaceutical sponsored research study for relapsing-remitting Multiple Sclerosis (MS) sufferers.
-
The study, to be published in the Dec. 3 advance online edition of Nature Immunology, lays the groundwork for a way to determine when a relapse is about to occur, and could eventually lead to a treatment to prevent relapses.
-
Generic drug maker Teva Pharmaceutical Industries Ltd. said Monday new data from a study of its multiple sclerosis drug reinforce previous information that the treatment reduces relapses of symptoms and may slow tissue damage associated with the disease.
-
Fatigue and functional deficits in multiple sclerosis (MS) patients were significantly improved during 4 weeks of inpatient rehabilitation, researchers reported
-
In a new study of patients diagnosed with multiple sclerosis (MS) after the age of 60, nearly half of relapsing patients with relapsing-remitting multiple sclerosis (RRMS) and patients with clinically isolated syndrome presented with signs of inflammation
-
Treatment of relapsing-remitting multiple sclerosis (MS) with glatiramer-acetate (glatiramer, Copaxone) is safe and effective, and it has a positive impact on average relapse rate and disease progression scores.
-
A new study showed that very active patients who received COPAXONE(R) (glatiramer acetate injection) therapy alone following short-term induction treatment with mitoxantrone experienced an 89 percent greater reduction (Pless than0.0001) compared to those
-
Schering AG Germany, announced today results from the subgroup analysis of the BENEFIT* study which showed that Betaferon® (interferon beta-1b) 250mcg treatment reduced the risk of developing clinically definite MS (CDMS) consistent
-
The study of 104 patients showed a statistically significant reduction in the total number of gadolinium enhancing T1 lesions observed on serial MRI scans of the brain at weeks 12, 16, 20 and 24 in the Rituxan-treated group compared to placebo
-
This study will evaluate the long-term safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.
